A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review

MENGLAN ZHAI and SHENG ZHANG
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China

Abstract. Background/Aim: Novel coronavirus infection in a cancer patient treated with immunotherapy, requires high attention. Case Report: Clinical and radiological data were obtained from the electronic medical record. Pharynx swab was tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA by reverse transcription-polymerase chain reaction (RT-PCR). The nasopharyngeal carcinoma patient developed fever on the third day after chemotherapy and immunotherapy. Laboratory examination showed lymphocytopenia. On the sixth day, chest computed tomography (CT) images showed bilateral scattered ground-glass opacities and reticulation. Pharynx swab was positive for SARS-CoV-2 nucleic acid and the patient was confirmed as having Coronavirus Disease 2019 (COVID-19). Unfortunately, despite aggressive treatment after the diagnosis of COVID-19, the patient died quickly. Conclusion: The patient with nasopharyngeal carcinoma in this case developed severe COVID-19 after receiving immunotherapy. For patients treated with immune checkpoint inhibitors (ICIs) in epidemic areas, the safety of ICIs in cancer patients infected with SARS-CoV-2 should be considered.

In recent years, ICIs for programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-cell lymphocyte-4 (CTLA-4) pathways have become the most promising tumor immunotherapy strategy (1), which play an important role in regulating self-tolerance and immune homeostasis by blocking the corresponding signal pathway. In addition, less well appreciated is the fact that immune checkpoint pathways also regulate antiviral immune responses and are therefore modulated by a number of viruses. Up-regulation of PD-1 and its ligands PD-L1 and PD-L2 is observed during acute virus infection. Experimental evidence suggests that insufficient signaling through the PD-1 pathway promotes immunopathology during acute infection by exaggerating primary T cell responses (2). Since December 2019, the novel coronavirus infection pandemic has become one of the common threats facing the world. Liang et al. (3) reported that cancer patients might have an increased risk of COVID-19 infection and a poor prognosis. It was also pointed out that cancer patients with COVID-19 who have recently been treated with anti-cancer therapy had a higher risk of severe events. Herein, we report a case of novel coronavirus infection in a nasopharyngeal carcinoma patient treated with anti-PD-1 monoclonal antibody to provide a reference for the safe use of ICIs during epidemic transmission.

Case Presentation

A 50-year-old man without known significant medical and smoking history, was admitted to hospital with nasopharyngeal carcinoma (cT4N2Mx, suspected liver metastasis). He was treated with gemcitabine-cisplatin (gemcitabine=1,000 mg/m² on days 1 and 8; cisplatin=75 mg/m² on days 1-2) plus anti-PD-1 monoclonal antibody Sintilimab (200 mg on day 1) therapy for the first time. On the third day after treatment, he developed fever, but there were no symptoms such as dry cough and dyspnea. Physical examination showed bilateral cervical lymph node enlargement. Previous medical histories include chronic viral hepatitis b and diabetes. Considering the prevalence of the novel coronavirus epidemic, laboratory tests showed that the white blood cell count was normal (7.21 G/L, 3.5-9.5 G/L), neutrophils increased (6.85 G/L, 1.8-6.3 G/L), and the absolute value of lymphocytes decreased (0.35 G/L, 1.1-3.2 G/L). IL-6 increased to 32.49 pg/ml and IL-10 increased to 6.77 pg/ml. CD4/CD8 ratio (3.54) was increased. C-reactive
protein (70.4 mg/l) was increased, procalcitonin was normal (less than 0.13 μg/l), and erythrocyte sedimentation rate was increased at 25 mm/h. Detection of respiratory pathogen spectrum antibody IgM (Mycoplasma pneumoniae IgM, chlamydia pneumoniae IgM, respiratory syncytial virus IgM, adenovirus IgM, coxsackievirus B-IgM) were all negative. Nucleic acids of three respiratory viruses (influenza A virus RNA, influenza B virus RNA, respiratory syncytial virus RNA) were all negative by nasal swabs. On the sixth day after treatment, the patient still had fever and new symptoms of dry cough and dyspnea. Chest CT images showed bilateral scattered ground-glass opacities and reticulation mainly distributed in a sub-pleural area, which were highly suspected to be caused by viral infection, as shown in Figure 1. The pharynx swab was positive for SARS-CoV-2 nucleic acid by RT-PCR assay approved by the China Food and Drug Administration. He was then referred to a designated critical hospital (Jin Yin-tan Hospital, Wuhan, PR China) for treatment as a confirmed case of COVID-19. After he was transferred to the designated hospital, the fever and dry cough persisted, and dyspnea worsened.

He was followed up by telephone, as his laboratory examination results and lung CT images in the designated hospital were not available. He received aggressive antiviral (ribavirin, arbidol, and hydroxychloroquine), glucocorticosteroids (methylprednisilone 2 mg/kg per day for 7 days), respiratory support and other supportive treatment. Antifungal (fluconazole) and wide-spectrum antibiotics (moxifloxacin meropenem) were used to prevent secondary infections. Unfortunately, he died 16 days after treatment. Written informed consent was obtained from the patient’s next to kin for publication of this case report.

Discussion

During the COVID-19 pandemic, the management of cancer patients treated with ICIs presents a major challenge. ICIs may enhance T cell activity, but it will damage the normal lung tissue at the same time, leading to ICI-related pneumonitis. Available literature reports that there might be potential overlap between ICI-related pneumonitis and COVID-19 associated interstitial pneumonia (4). The incidence of ICI-related pneumonitis in patients receiving anti-PD-1/PD-L1 monotherapy and anti-PD-1 combined with anti-CTLA-4 therapy were 2.5-5% and 7-10%, respectively (5). The median time to onset of ICI-related pneumonitis was 2.8 months (6). The febrile symptoms of this patient appeared within 1 week after the first treatment with the PD-1 inhibitor, and ICI-related pneumonitis was basically excluded. His fever might also have been caused by neutropenia after chemotherapy. In severe cases, it would even be complicated with bacterial pneumonia. However, his neutrophil count was normal. Combined with the positive result of the novel coronavirus nucleic acid test, SARS-CoV-2 infection was confirmed.

Studies have indicated that immunotherapy increases the risk of severe COVID-19 events (7, 8). Bonomi et al. (9) and Di Noia et al. (10) separately reported that a non-small cell lung cancer patient with long-term anti-PD-1 monotherapy died quickly after infected with COVID-19. Seven of the 28 cancer patients infected with COVID-19 reported by Zhang et al. (11) were lung cancer patients. Among them, one patient received anti-CTLA-4/anti-PD-1 combination therapy and chemotherapy combined with anti-PD-1 monotherapy therapy 3 months and 14 days before onset of symptoms, respectively. She developed a severe case of COVID-19. Wu et al. (12) reported that 11 cancer patients with COVID-19 received immunotherapy, of whom 7 developed severe disease and 4 died of COVID-19. Meanwhile, it was pointed out that patients who received more than 3 cycles of immunotherapy had a higher risk of severe events, but the difference was not statistically significant, probably because of the very small sample. Currently, there is no specific drug for COVID-19, and the treatment is mainly antiviral, antibacterial, oxygen therapy and other comprehensive treatment (13). In this study, the patient received immunotherapy before getting SARS-CoV-2. He finally died of ineffectiveness despite active treatment. Several studies have shown that the severity of COVID-19 is independent of immunotherapy (14-16). Besides, findings have indicated that there is no correlation between the interval of the last use of ICIs and the severity of COVID-19 (12, 15). Szabados et al. (17) reported four cancer patients who had received immunotherapy before infected with COVID-19 (two patients with metastatic urothelial cancer and another two with metastatic renal cancer). No severe events occurred whether they were previously treated with anti-PD-1 monotherapy or anti-PD-1 combined with anti-CTLA-4. Li et al. (18) reported that a lymphoma patient undergoing intensive immunochemotherapy developed grade 4 myelosuppression with SARS-CoV-2 infection. After comprehensive treatment, his COVID-19 was cured.

The severity of COVID-19 in cancer patients with immunotherapy may be related to the mechanism of lung injury caused by immunotherapy and SARS-CoV-2 infection. However, to date, the mechanism of lung injury caused by SARS-CoV-2 infection is not yet entirely clear. In this case, the absolute value of lymphocytes decreased and most inflammatory factors increased. This result suggested that COVID-19 might be related to the "cytokine storm" caused by the overreaction of the immune system caused by viral infection and the release of a large amount of cytokines, tumor necrosis factors and others (19). Glucocorticoids can suppress inflammatory cytokine storms and can be used for ICI-related pneumonitis and COVID-19 (20). Survival of this patient failed to improve after low-dose
glucocorticoid therapy, which might be related to the function of glucocorticoid in inhibiting the body’s immune response and delaying virus clearance (21). ICI exposure may enhance the cytokine storm associated with COVID-19 and further aggravate COVID-19 (22). PD-1 inhibitors can enhance the antiviral immune response in the process of virus infection by inhibiting PD-1 signaling pathway (23), which can theoretically improve the disease. Therefore, based on the current researches, it cannot be proved that severe pneumonia caused by SARS-COV-2 infection is related to immunotherapy.

**Conclusion**

The patient with nasopharyngeal carcinoma in this case developed severe COVID-19 after receiving immunotherapy. However, the effect of immunotherapy on COVID-19 remains unclear. Therefore, under the circumstances that the spread of the epidemic has not been completely controlled, further studies are needed to explore the safety of ICIs in cancer patients infected with COVID-19.

**Conflicts of Interest**

The Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Authors’ Contributions**

SZ made substantial contributions to the conception and design of the work. SZ and MZ made substantial contributions to the laboratory analysis and interpretation of data. SZ and MZ made substantial contributions to the acquisition of clinical data and their interpretation. SZ and MZ were involved in drafting the manuscript. SZ was involved in critically revising the manuscript for important intellectual content. SZ and MZ read and approved the final manuscript.

**Acknowledgements**

The Authors would like to thank the health care workers who are involved in the fight against COVID-19.
References


Received August 12, 2020
Revised August 27, 2020
Accepted August 28, 2020